Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.
Song JY, Choi WS, Heo JY, Lee JS, Jung DS, Kim SW, Park KH, Eom JS, Jeong SJ, Lee J, Kwon KT, Choi HJ, Sohn JW, Kim YK, Noh JY, Kim WJ, Roman F, Ceregido MA, Solmi F, Philippot A, Walls AC, Carter L, Veesler D, King NP, Kim H, Ryu JH, Lee SJ, Park YW, Park HK, Cheong HJ.
Song JY, et al. Among authors: kim h, kim yk, kim wj, kim sw.
EClinicalMedicine. 2022 Jul 22;51:101569. doi: 10.1016/j.eclinm.2022.101569. eCollection 2022 Sep.
EClinicalMedicine. 2022.
PMID: 35879941
Free PMC article.